Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in... This was a randomized, double-blind, placebo-controlled comparison of the efficacy and safety of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR). Outpatients with DSM-III-R major depression were randomly assigned to venlafaxine XR, 75 mg once daily, venlafaxine IR, 37.5 mg twice daily, or placebo for a maximum of 12 weeks. If the response was inadequate after 2 weeks of treatment, the dosage of venlafaxine XR or IR could be increased to 150 mg daily. The primary efficacy variables were the 21-item Hamilton Depression (HAM-D) Rating Scale total score and depressed mood item, the Montgomery–Asberg Rating Scale (MADRS) total scores, and the Clinical Global Impressions (CGI) severity scale. Two hundred seventy-eight patients were evaluated for efficacy. Venlafaxine XR was significantly superior (p < 0.05) to placebo beginning at week 2 for the HAM-D, week 3 for the MADRS, and week 4 for the CGI severity. Similarly, venlafaxine IR was significantly superior (p < 0.05) to placebo beginning at week 2 on the HAM-D total and depressed mood item, week 3 on the MADRS total, and week 6 on the CGI severity scales. Venlafaxine XR exhibited superiority (p < 0.05) over venlafaxine IR at week 12 for all efficacy variables. The most common treatment-emergent adverse event with venlafaxine XR was nausea. The incidence of nausea was highest during the first 2 weeks with a low likelihood of developing nausea thereafter. The results of this study indicate that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

Cunningham, Lynn
Annals of Clinical Psychiatry , Volume 9 (3) – Sep 18, 2004
Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/once-daily-venlafaxine-extended-release-xr-and-venlafaxine-immediate-kmMZX4Uaib
Publisher
Springer Journals
Copyright
Copyright © 1997 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1026277907818
Publisher site
See Article on Publisher Site

Abstract

This was a randomized, double-blind, placebo-controlled comparison of the efficacy and safety of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR). Outpatients with DSM-III-R major depression were randomly assigned to venlafaxine XR, 75 mg once daily, venlafaxine IR, 37.5 mg twice daily, or placebo for a maximum of 12 weeks. If the response was inadequate after 2 weeks of treatment, the dosage of venlafaxine XR or IR could be increased to 150 mg daily. The primary efficacy variables were the 21-item Hamilton Depression (HAM-D) Rating Scale total score and depressed mood item, the Montgomery–Asberg Rating Scale (MADRS) total scores, and the Clinical Global Impressions (CGI) severity scale. Two hundred seventy-eight patients were evaluated for efficacy. Venlafaxine XR was significantly superior (p < 0.05) to placebo beginning at week 2 for the HAM-D, week 3 for the MADRS, and week 4 for the CGI severity. Similarly, venlafaxine IR was significantly superior (p < 0.05) to placebo beginning at week 2 on the HAM-D total and depressed mood item, week 3 on the MADRS total, and week 6 on the CGI severity scales. Venlafaxine XR exhibited superiority (p < 0.05) over venlafaxine IR at week 12 for all efficacy variables. The most common treatment-emergent adverse event with venlafaxine XR was nausea. The incidence of nausea was highest during the first 2 weeks with a low likelihood of developing nausea thereafter. The results of this study indicate that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 18, 2004

References

  • Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
    Muth, EA; Haskins, JT; Moyer, JA
  • A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia
    Benkert, O; Gründer, G; Wetzel, H
  • A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
    Clerc, GE; Ruimy, P; Verdeau-Pailles, J
  • A comparison of venlafaxine, trazodone, and placebo in major depression
    Cunningham, LA; Borison, RL; Carman, JS
  • A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
    Dierick, M; Ravizza, L; Realini, R
  • Double-blind, randomized, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with mild to moderate depression
    Lecrubier, Y; Moon, CAL; Schifano, F
  • Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients
    Schweizer, E; Feighner, J; Mandos, L
  • Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression
    Shrivastava, R; Cohn, C; Crowder, J
  • A double-blind, randomized, 12-week comparison study of the safety and efficiency of venlafaxine and fluoxetine 20 mg in moderate to severe depression in general practice
    Tylee, A; Bowden, M; Reynolds, A
  • Venlafaxine: A review of its pharmacology and therapeutic potential in depression
    Holliday, SM; Benfield, P
  • A rating scale for depression
    Hamilton, MA
  • A new depression scale designed to be sensitive to change
    Montgomery, SA; Asberg, M.
  • ECDEU Assessment Manual for Psychopharmacology, Revised
    Guy, W
  • Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: A meta-analysis
    Entsuah, R; Upton, GV; Rudolph, R.
  • Effectiveness of venlafaxine in patients hospitalized with major depression and melancholia
    Guelfi, JD; White, C; Hackett, D
  • Venlafaxine in depressed geriatric outpatients: An open-label clinical study
    Khan, A; Rudolph, R; Baumel, B
  • Progress in psychiatry
    Michels, R; Marzuk, PM
  • The pharmacologic treatment of depression
    Potter, WZ; Rudorfer, MV; Manji, H.
  • Principles and Practice of Psychopharmacotherapy
    Preskorn, SH; Janicak, PG; Davis, JM
  • Drug-drug interactions involving antidepressants: Focus on venlafaxine
    Ereshefsky, L
  • A placebo-controlled comparative study of the effects of blood pressure and antidepressant efficacy of venlafaxine and imipramine
    Ferguson, J; Khan, A; Kucharik, R